Effect of Oral Erythropoietin in neonatal with hypoxic ischemic encephalopathy
Phase 1
Recruiting
- Conditions
- Ischemic hypoxic encephalopathy.Hypoxic ischemic encephalopathy [HIE]P91.6
- Registration Number
- IRCT20140907019076N2
- Lead Sponsor
- Mashhad University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 100
Inclusion Criteria
Gestational age more than and equal to 37 weeks
prenatal asphyxia
Grade 2 and 3 encephalopathy
Conscious consent of parents
Exclusion Criteria
Birth weight <2200 g
A genetic or congenital disease that affects nerve growth or requires multiple surgeries
Head circumference <30 cm
Polycythemia
The infant should participate in another intervention period during hospitalization
Asphyxia cases without HIE
Metabolic diseases
Confirmed infection
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Effect of Oral Erythropoietin on tolerance of oral feeding, Prevention of Complications and reduction of mortality in neonatal with hypoxic ischemic encephalopathy. Timepoint: In the erythropoietin intervention group, orally within the first 48 hours of birth at a dose of 400 units per kilogram daily for 5 days (days 7,5,3,1,2). Method of measurement: By mouth or stomach catheter.
- Secondary Outcome Measures
Name Time Method